Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Research and Markets: Handbook of Metastatic Breast Cancer

Research and Markets
Posted on: 05 Oct 12

Research and Markets ( has announced the addition of the "Handbook of Metastatic Breast Cancer" book to their offering.

About one third of women diagnosed with breast cancer will develop metastatic disease and subsequently die from their advanced breast cancer. Recent developments with novel systemic drugs, palliative surgical techniques and diagnostic imaging have given hope for the treatment of patients whose breast cancer has spread beyond its primary tumour.

Written by a team from leading cancer centres in Europe, including the UK's Royal Marsden Hospital, the Handbook of Metastatic Breast Cancer, Second Edition provides advanced scientific information and guidance on clinical problems associated with metastatic breast cancer.

Highlights of the Second Edition include:

- New chapters on specialist treatment options, gene expression signatures, biomarkers, and specialist support services for patients and their families

- Significant updates to chapters discussing systemic treatments for breast cancer, including endocrine therapy, chemotherapy, targeted therapies, and bisphosphonates

- Up-to-date information on diagnostic imaging and tumour assessment, including positron emission tomography and computed tomography

- Up-to-date information on local treatment options for neurological, thoracic, orthopaedic, and hepatic complications

This handbook will be a practical and comprehensive resource for medical and clinical oncologists, breast surgeons and radiologists, as well as neurosurgeons, clinical scientists, orthopaedic and thoracic surgeons.

Key Topics Covered:


2.The prognostic and predictive value of gene expression signatures in breast cancer

Section I - Systemic Treatments

3.Targeting ER positive metastatic breast cancer

4.Targeting HER2+ and Trastuzumab Resistant metastatic breast cancer

5.Targeting Triple Negative Sporadic and hereditary BRCA related metastatic Breast Cancer

6.Chemotherapy and metastatic breast cancer

7.Bisphosphonates and their role in metastatic breast cancer

8.Targeting Angiogenesis in Metastatic Breast Cancer

Section II - Imaging and Response Assessment

9.Imaging in the management of metastatic breast cancer

10.Positron emission tomography/computed tomography in metastatic breast cancer

11.Novel biomarker approaches for improving therapeutic strategies in metastatic breast cancer

Section III - Local Treatment Options

12.Palliative radiotherapy in the management of metastatic breast cancer

13.Management of neurological complications in metastatic breast cancer

14.Thoracic complications

15.Orthopaedic complications

16.Thermal ablation of hepatic metastases

17.Palliative Care and Metastatic Breast Cancer

18.Specialist Support Services and Information Needs for Patients

For more information visit

Business Wire

Last updated on: 05/10/2012

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.